Navigation Links
Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
Date:10/22/2008

antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candida
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
6. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Avicena Group to Present at Noble Financial Conference
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Calif., June 2 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... will present a company update at the Goldman Sachs 30th Annual ... 2009 at 9:00 a.m. ET. , , Interested ... via the investor section of the BioMarin website, www.BMRN.com ...
... , SAN DIEGO, June 2 Orexigen(R) Therapeutics, Inc. (Nasdaq: ... treatment of obesity, today announced the schedule of its upcoming ... the American Diabetes Association (ADA) 69th Scientific Sessions, June 5-9, ... (ENDO), June 10-13, 2009. , , , ...
... June 2 Micromet, Inc. (Nasdaq: MITI ), a ... inflammation and autoimmune diseases, today announced that it will host a ... on June 5th and 6th at the 14th Congress of the ... company,s website at www.micromet-inc.com . , , ...
Cached Biology Technology:BioMarin to Present at the Goldman Sachs Healthcare Conference 2Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings 2Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 2Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 3Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 4
(Date:4/17/2014)... of forests in the Amazon help create tinderbox ... rapid and widespread forest loss during drought years, ... show that forests in the Amazon could reach ... forest fires lead to large-scale loss of trees, ... professor of geography, Penn State. , "We documented ...
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... is the process whereby the genetic information of ... as proteins, which have numerous different functions in ... important intermediary during gene expression, by relating the ... involved in manufacturing proteins. , By examining ... present in an organism at a given time, ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2
... goats and other animals that have suffered from neglect, according ... In this first scientific study of rescued animals, the researchers ... poor welfare, such as inappropriate diet, and lack of space ... spatial awareness test, which involved giving the animals an opportunity ...
... special issue of Technology and Innovation ... ), devoted to studies on medical technology and health ... from new technologies to reduce the cost of health ... special issue of Technology and Innovation on ...
... gas development expands nationwide, policymakers, communities and public health ... as a means of predicting the effects of drilling ... the Colorado School of Public Health. The report, ... Public Health , highlights lessons learned when scientists from ...
Cached Biology News:Rescue me: New study finds animals do recover from neglect 2Technology transforms health care 2Technology transforms health care 3Health impact assessments prove critical public health tool 2
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: